CLAIMS:

1. Crystalline Form I of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate,

characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 10.0, 18.1, 18.6, 20.1, and 23.9 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation.

2. The crystalline form of claim **1**, wherein the XRPD pattern further comprises a peak at 20.5 degrees, ± 0.5 degrees, 2θ.

3. The crystalline form of claim **1** or **2**, wherein the XRPD pattern is substantially similar to the pattern of Figure 1.

4. The crystalline form of any one of claims 1 to 3, substantially free of other polymorphic forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate.

5. The crystalline form of any of claims **1** to **3**, having less than 5% by weight of any other polymorphic form.

6. The crystalline form of any one of claims **1** to **3**, having less than 1% by weight of any other polymorphic form.

7. The crystalline form of any one of claims **1 to 6**, further characterized by a melting point of about 253°C.

8. The crystalline form of any one of claims **1** to **7,** further characterized by an aqueous solubility of about 8.3 mg/mL at 25°C.

9. A pharmaceutical composition, comprising the crystalline form of any one of claims **1** to **8**, and a pharmaceutically acceptable carrier.

10. Use of the crystalline form of any one of claims **1** to **8**, or the pharmaceutical composition of claim **9**, in the preparation of a medicament for treating of a disease or condition selected from the group consisting of:

diabetic macular edema, diabetic retinopathy, hereditary angioedema with C1 inhibitor deficiency, acute liver injury, inflammation, anaphylaxis, chemical-sensitized renal damage, ischemic stroke, hemorrhagic stroke, hypertension, vascular complications of hypertension, retinopathy, nephropathy, cerebrovascular edema, pulmonary hypertension, inflammation, pain, acute myocardial infarction, deep vein thrombosis, complications from fibrinolytic treatment, angina, angioedema, sepsis, arthritis, complications of cardiopulmonary bypass surgery, capillary leak syndrome, inflammatory bowel disease, diabetes, diabetic retinopathy, diabetic macular edema, diabetic nephropathy, diabetic neuropathy, age-related macular degeneration, retinal vein occlusions, brain edema, ischemia-reperfusion injury, cancer-related angiogenesis, asthma, anaphylaxis, and cerebrovascular complications of Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, Central Nervous System infections, and glioblastoma multiforme.

11. The use of claim **10**, wherein the disease or condition is diabetic macular edema.